News coverage about OncoSec Medical (NASDAQ:ONCS) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.5637578753805 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

Several equities analysts have issued reports on the company. Maxim Group set a $5.00 price target on OncoSec Medical and gave the company a “buy” rating in a research note on Saturday, June 3rd. ValuEngine raised OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, July 14th. Dawson James reissued a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research note on Thursday, July 6th. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a research note on Wednesday, June 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of OncoSec Medical in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. OncoSec Medical has a consensus rating of “Buy” and a consensus target price of $5.33.

Shares of OncoSec Medical (NASDAQ ONCS) traded down 1.735% during trading on Tuesday, hitting $0.963. The stock had a trading volume of 10,850 shares. The stock’s market capitalization is $20.38 million. OncoSec Medical has a 52 week low of $0.88 and a 52 week high of $2.08. The firm has a 50 day moving average price of $0.98 and a 200-day moving average price of $1.11.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/26/oncosec-medical-oncs-receiving-somewhat-favorable-press-coverage-analysis-finds.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.